Planta Med 2019; 85(14/15): 1143-1149
DOI: 10.1055/a-1012-7034
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Rhein Augments Antiproliferative Effects of Atezolizumab Based on Breast Cancer (4T1) Regression

Zhanyun Shen
1   College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, P. R. China
2   School of Traditional Chinese Medicine, Zhejiang Pharmaceutical College, Ningbo, P. R. China
,
Bo Zhu
1   College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, P. R. China
,
Jiao Li
1   College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, P. R. China
,
Luping Qin
1   College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, P. R. China
› Author Affiliations
Further Information

Publication History

received 28 May 2019
revised 29 August 2019

accepted 04 September 2019

Publication Date:
26 September 2019 (online)

Preview

Abstract

Rhein, an anthraquinone extracted from rhubarb, is used in traditional Chinese medicine for diuresis, diarrhoea, inflammation, and immune regulation. Atezolizumab, a programmed cell death ligand 1 monoclonal antibody, is mainly used to treat bladder cancer and non-small cell lung cancer unresponsive to chemotherapy. We explored the effects of rhein and atezolizumab in combination on breast cancer. Mice with established 4T1 breast cancer xenografts were administered rhein (10 mg/kg) and atezolizumab (10 mg/kg), alone and in combination, and the effects on tumour growth were evaluated. The proportion of CD8+ T cells in the spleen and tumour tissue, the levels of TNF-α, and interleukin-6 in serum as well as the mRNA levels of apoptotic factors (caspase-3, caspase-8, caspase-9, and Bax/Bcl-2) were also evaluated. All of the treatment groups had inhibitory effects on the xenograft tumour growth, with results that were significantly different from those in the control group. In addition, the proportion of CD8+ T cells in the spleen and tumour was significantly increased in the combination therapy group and was significantly different from the other treatment groups. The serum levels of TNF-α and IL-6 were significantly increased in the rhein and combination therapy groups. Finally, the levels of various apoptotic factors in tumour tissues were significantly higher in the combination treatment group than those in the other groups. Administration of rhein, atezolizumab, or their combination all had therapeutic effects on 4T1 breast cancer xenografts in mice, with the combination treatment having stronger effects.